Related Experiment Videos
Prostatic acid phosphatase and prostate specific antigen in liver disease
A Kadayifci1, M Benekli, H Simşek
1Department of Internal Medicine, Hacettepe University Medical School, Ankara, Turkey.
International Urology and Nephrology
|January 1, 1996
Summary
Serum prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) levels remain reliable for prostate cancer monitoring in chronic liver disease patients. These biomarkers maintain their diagnostic specificity despite liver conditions.
Area of Science:
- Oncology
- Hepatology
- Biochemistry
Background:
- Chronic liver diseases, including cirrhosis and chronic active hepatitis (CAH), can affect various bodily functions.
- Prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) are key biomarkers for prostate health.
Purpose of the Study:
- To investigate the reliability of serum PSA and PAP levels for prostate cancer diagnosis and monitoring in patients with chronic liver conditions.
- To assess if liver cirrhosis or CAH impacts the specificity of PSA and PAP as prostate cancer biomarkers.
Main Methods:
- Serum PSA and PAP concentrations were measured in 51 liver cirrhosis patients, 37 CAH patients, and 26 healthy controls.
- Statistical analysis was performed to compare mean PSA and PAP values between the groups.
Main Results:
- Slightly elevated PSA levels were observed in 2 cirrhotic patients; no elevations were found in CAH patients or controls.
- Minor increases in PAP levels were noted in 2 cirrhotic patients, 2 CAH patients, and 1 control.
- No significant differences in mean PSA and PAP levels were found between the patient groups and controls (p > 0.05).
Conclusions:
- Serum PSA and PAP levels maintain their diagnostic reliability and specificity for prostate cancer in patients with chronic liver disease.
- These biomarkers can be effectively used for diagnosing and monitoring prostate cancer in individuals with liver cirrhosis and CAH.